783P Impact of Cemiplimab on Quality of Life (qol), Functioning and Symptoms in Patients (pts) with Recurrent/metastatic (R/M) Cervical Carcinoma: Results from EMPOWER-Cervical 1/Gog-3016/Engot-cx9
ANNALS OF ONCOLOGY(2021)
摘要
Cemiplimab significantly improved overall survival in pts with R/M cervical cancer after first-line (1L) platinum-based chemotherapy (chemo) (NCT03257267; ESMO-VP-2021). We now report patient-reported QoL, functioning and symptoms from the trial.
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要